Zelira Therapeutics

Zelira is a provider of preclinical services for diabetes, breast and brain cancer.

Business Model:

Revenue: $0

Employees: 1-10

Detailed Zelira Therapeutics Information

Geographic Data

Zelira Therapeutics headquarters map

Address: 140 St Georges Terrace

City: Perth

State: western australia

Zip: 6000

Country: AU

Financial Info

Stage:

post ipo equity

Raised Last:

$5M

Raised Total:

$5M

Metrics

4,043,492Website Global Rank

2,940Website Monthly Traffic

Twitter Followers

Description

Zelira is a provider of preclinical services for diabetes, breast and brain cancer.

Contact Phone:

Contact Email:

Zelira Therapeutics went public on 8/1/2003 on the Australian Securities Exchange

Listed Exchange:
Australian Securities Exchange

IPO Date:
8/1/2003

Ticker Symbol:
ZLD

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
10/2021 Post-IPO Equity $1.5M
10/2021 Private Placement $3.5M
2/2020 Private Placement $4.6M
8/2020 Private Placement $6.2M
2/2020 Post-IPO Equity $4.6M
Announced Date Name Price
2/2022 Health House

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research